Nestlé divests its peanut allergy treatment business
Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company that specialises in the diagnosis and treatment of allergies. The transaction was closed upon signing.
Last year, Nestlé announced it would conduct a strategic review of Palforzia. It will now receive milestone payments and ongoing royalties from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said Nestlé is confident that Stallergenes Greer will take Palforzia forward, allowing Nestlé Health Science to focus on its strengths and growth drivers.
There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
Danone to acquire Made Group
Danone has announced its plans to acquire MADE Group, which is expected to be completed in the...
Poultry and egg producers in lockdown as avian flu detected in WA
While there has been no detection of the H5N1 avian influenza in commercial poultry, some...
WA dog food manufacturer seals SE Asia export deal
West Australian dog food manufacturer Nutri-Mate Pet Foods has partnered with Pet World...
